Loading
Life sciences · Journal article
Clinical & Experimental Allergy · September 28, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Asthma and allergic diseases represent a substantial global health burden, frequently compounded by the modern epidemics of obesity and metabolic syndrome to create a complex immunometabolic challenge. The emerging epithelial barrier hypothesis provides a mechanistic framework linking environmental exposures to systemic inflammation and metabolic dysfunction. Standard therapies often fail to address these underlying systemic drivers, particularly in difficult-to-treat phenotypes like obesity-related asthma. This review explores the dual-action potential of glucagon-like peptide-1 receptor agonists (GLP-1RA) as a novel therapeutic strategy. Beyond their established roles in glycemic control and weight loss, GLP-1RA exert direct, weight-independent immunomodulatory effects. Mechanistic evidence demonstrates that the GLP-1 receptor (GLP-1R) is expressed on key immune cells, including eosinophils, macrophages, and Group 2 innate lymphoid cells. Agonism of these receptors suppresses Type 2 (T2) inflammation by reducing cytokine production (IL-5, IL-13) and upstream alarmins (IL-33). Furthermore, GLP-1R signalling enhances regulatory T cell function and may restore epithelial barrier integrity in both the gut and airways. Clinical observations suggest that GLP-1RA initiation improves asthma control and reduces exacerbations, often independently of body mass index reduction. However, prospective trials utilizing specific T2 biomarkers are needed to confirm these direct cellular mechanisms in humans. Transitioning to an immunometabolic approach with GLP-1RA may offer a comprehensive solution for patients at the intersection of metabolic and allergic disease.